{
    "clinical_study": {
        "@rank": "75592", 
        "arm_group": [
            {
                "arm_group_label": "Gemigliptin", 
                "arm_group_type": "Experimental", 
                "description": "Participant will remain gemigliptin 50mg throughout entire study (52 weeks)."
            }, 
            {
                "arm_group_label": "Placebo to linagliptin", 
                "arm_group_type": "Other", 
                "description": "Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52."
            }
        ], 
        "brief_summary": {
            "textblock": "Therapuetic options are limited for Type 2 Diabetes Mellitus (T2DM) pateints with renal\n      impairment. This clinical study is to asses safety and efficacy of the DPP-4 inhibitor\n      gemigliptin in patients with type 2 DM and moderate or severe renal impairment for long-term\n      peirod (52 weeks)."
        }, 
        "brief_title": "A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 DM Patients With Moderate or Severe Renal Impairment", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Type 2 Diabetes Mellitus\n\n          -  Patients with moderate or  severe renal insufficiency\n\n          -  All patients give written informed consent\n\n        Exclusion Criteria:\n\n          -  Has type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  Is on dialysis or is likely to need dialysis during the study\n\n          -  Has active liver disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "148", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968044", 
            "org_study_id": "LG-DPCL015"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gemigliptin", 
                "intervention_name": "Gemigliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to linagliptin", 
                "intervention_name": "Placebo to Linagliptin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "BI 1356"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "renal impairment", 
        "lastchanged_date": "October 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }, 
            "investigator": {
                "last_name": "DR Cha, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter,Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase IIIb Study to Evaluate the Safety and Efficacy After 12 Weeks Administration of Gemigliptin and Placebo in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment With an Additional 40 Weeks, Double-blind,Active-controlled, Double-dummy,Long-term Extension Study", 
        "overall_contact": {
            "last_name": "Jiyoung Min, M.Sc", 
            "phone": "82-26924-3107"
        }, 
        "overall_official": {
            "affiliation": "Korea University", 
            "last_name": "DR Cha, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Republic of Korea:Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "HbA1c change", 
            "safety_issue": "No", 
            "time_frame": "HbA1c change from baseline to week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968044"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "HbA1c Change", 
                "safety_issue": "No", 
                "time_frame": "HbA1c change from baselint to week 6, 52"
            }, 
            {
                "measure": "FPG", 
                "safety_issue": "No", 
                "time_frame": "FPG change from baseline to week 6,12,52"
            }, 
            {
                "measure": "Glycated albumin", 
                "safety_issue": "No", 
                "time_frame": "Glycated albumin change from baseline to week 6,12,52"
            }, 
            {
                "measure": "Fructosamin", 
                "safety_issue": "No", 
                "time_frame": "Fructosamin change from baseline to week 6,12,52"
            }, 
            {
                "measure": "Waist", 
                "safety_issue": "No", 
                "time_frame": "Waist change from baseline to week 12,52"
            }, 
            {
                "measure": "HbA1c responser (HbA1c<7.0%)", 
                "safety_issue": "No", 
                "time_frame": "HbA1c responser rate at week 12,52"
            }, 
            {
                "measure": "Fasting serum C-peptide", 
                "safety_issue": "No", 
                "time_frame": "Fasting serum C-peptide change from baseline to week 12,52"
            }, 
            {
                "measure": "Fasting Lipid parameters", 
                "safety_issue": "No", 
                "time_frame": "Fasting Lipid parameters change from baseline to week 12,52"
            }, 
            {
                "measure": "Albuminuria", 
                "safety_issue": "No", 
                "time_frame": "Albuminuria change from baseline to week 12,52"
            }
        ], 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}